Citations

Clear

3042 citation(s) found for "Kumar, S".

Ovatodiolide Suppresses Oral Cancer Malignancy by Down-Regulating Exosomal Mir-21/STAT3/β-Catenin Cargo and Preventing Oncogenic Transformation of Normal Gingival Fibroblasts
Chen, Jia‐Hong , Wu, Alexander T.H. , Bamodu, Oluwaseun Adebayo , Yadav, Vijesh Kumar , Chao, Tsu-Yi, Tzeng, Yew‐Min , Hsiao, Michael , Lee, Jih-Chin, Wu, Alexander T H , Chen, Jia-Hong , Mukhopadhyay, Debabrata , Lee, Jih‐Chin

Mayo Clinic

Cancers | December 24, 2019 | Volume: 12 | Issue: 1 | Pages: 56

10.3390/cancers12010056 | PMID 31878245 Get It

Oral squamous cell carcinoma (OSCC) is among the most commonly diagnosed malignancies in the world. Patients with OSCC often develop treatment resistance, resulting in a poor prognosis. Mounting evidence indicates that interactions between cancerous cells and other components of the tumor microenvironment (TME) determine their response to treatment. Herein, we examined the role of cancer stem cell-derived extracellular vesicles (CSC_EVs) generated from CAL27 and SCC-15 OSCC cells in the development of cisplatin (CDDP) resistance. We demonstrated that CSC_EVs enhance CDDP resistance, clonogenicity, and the tumorsphere formation potential of OSCC cells. Our bioinformatics analyses revealed that OSCC_EVs are enriched with microRNA (miR)-21-5p and are associated with increased metastasis, stemness, chemoresistance, and poor survival in patients with OSCC. Mechanistically, enhanced activity of CSC_EVs was positively correlated with upregulated β-catenin, phosphatidylinositol-3 kinase (PI3K), signal transducer and activator of transcription 3 (STAT3), mammalian target of rapamycin (mTOR), and transforming growth factor (TGF)-β1 messenger (m)RNA and protein expression levels. CSC_EVs also conferred a cancer-associated fibroblast (CAF) phenotype on normal gingival fibroblasts (NGFs), with the resultant CAFs enhancing the oncogenicity of OSCC cells. Interestingly, treatment with ovatodiolide (OV), the bioactive component of Anisomeles indica, suppressed OSCC tumorigenesis by reducing the cargo content of EVs derived from CSCs, suppressing self-renewal, and inhibiting the NGF-CAF transformation by disrupting EV-TME interactions. Moreover, by suppressing miR-21-5p, STAT3, and mTOR expressions in CSC_EVs, OV re-sensitized CSCs to CDDP and suppressed OSCC tumorigenesis. In vivo, treatment with OV alone or in combination with CDDP significantly reduced the tumor sphere-forming ability and decreased EV cargos containing mTOR, PI3K, STAT3, β-catenin, and miR-21-5p. In summary, our findings provide further strong evidence of OV’s therapeutic effect in OSCC.
Daratumumab in untreated newly diagnosed multiple myeloma
Abdallah, Nadine , Kumar, Shaji , Kumar, Shaji K

Mayo Clinic

Therapeutic Advances in Hematology | December 23, 2019 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/2040620719894871 | PMID 31903177 Get It

The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies. Daratumumab, a fully human monoclonal antibody targeting CD38, has shown clinical efficacy in relapsed/refractory multiple myeloma both as monotherapy and in combination with other drugs, including novel agents. More recently, promising results have been reported in patients with untreated newly diagnosed multiple myeloma (NDMM). Clinical trials thus far have shown enhanced efficacy and tolerability of several daratumumab-based combinations in both transplant ineligible and eligible patients, without compromising transplant ability. However, benefit in high-risk subpopulations is still unclear. A subcutaneous formulation of daratumumab has been introduced to decrease the risk of infusion reactions, with preliminary results showing non-inferior efficacy. The antimyeloma activity of daratumumab is achieved through multiple mechanisms including direct, Fc-dependent, and immunomodulatory mechanisms. Enhanced efficacy of daratumumab in combination with immunomodulatory drugs and proteasome inhibitors is supported by preclinical data showing synergism. This review will focus on the role of daratumumab in untreated NDMM patients, highlighting the results of major clinical trials, and listing ongoing trials that are evaluating various daratumumab-based combinations in this setting.
Enhancing the R‐ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells
Gonsalves, Wilson I. , Jevremović, Dragan , Nandakumar, Bharat , Dingli, David , Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Leung, Nelson , Fonder, Amie , Hobbs, Miriam, Hwa, Yi L. , Muchtar, Eli , Warsame, Rahma , Kourelis, Taxiarchis , Russell, Stephen J. , Lust, John A., Lin, Yi , Siddiqui, Mustaqeem , Kyle, Robert A. , Kumar, Shaji , Dispenzieri, Angela , Leung, Nelson , Hwa, Yi Lisa, Warsame, Rahma , Kourelis, Taxiarchis , Russell, Stephen, Siddiqui, Mustaqeem A, Gertz, Morie A , Rajkumar, S Vincent , Muchtar, E , Gonsalves, Wilson , Russell, Stephen J , Jevremovic, Dragan , Siddiqui, Mustaqeem A , Dingli, David , Lin, Yi , Dispenzieri, Angela , Buadi, Francis K. , Go, Ronald S. , Gertz, Morie A. , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | December 23, 2019 | Volume: 95 | Issue: 3 | Pages: 310-315

10.1002/ajh.25709 | PMID 31867775 Get It

AbstractOur prior studies identified the prognostic significance of quantifying cPCs by multiparametric flow cytometry (MFC) in newly diagnosed multiple myeloma (NDMM) patients. We evaluated if a similar quantification of cPCs could add prognostic value to the current R‐ISS classification of 556 consecutive NDMM patients seen at the Mayo Clinic, Rochester from 2009 to 2017. Those patients that had ≥5 cPCs/μL and either R‐ISS stage I or stage II disease were re‐classified as R‐ISS IIB stage for the purposes of this study. The median time to next therapy (TTNT) and overall survival (OS) for patients with ≥5 cPCs/μL at diagnosis was as follows: R‐ISS I (N = 110) ‐ 40 months and not reached; R‐ISS II (N = 69) ‐ 30 and 72 months; R‐ISS IIB (N = 96) ‐ 21 and 45 months and R‐ISS III (N = 281) ‐ 20 and 47 months respectively. Finally, ≥ 5 cPCs/μL retained its adverse prognostic significance in a multivariable model for TTNT and OS. Hence, quantifying cPCs by MFC can potentially enhance the R‐ISS classification of a subset of NDMM patients with stage I and II disease by identifying those patients with a worse than expected survival outcome.
Clinical and Biochemical Phenotypes in a Family With ENPP1 Mutations
Kotwal, Anupam , Kumar, Rajiv , Murthy, Vishakantha , Schultz‐Rogers, Laura , Zimmermann, Michael T. , Lanpher, Brendan C. , Stabach, Paul R., Klee, Eric W. , Braddock, Demetrios T. , Wermers, Robert A. , Schultz-Rogers, Laura, Lanpher, Brendan, Klee, Eric, Braddock, Demetrios T , Kudva, Yogish C , Zimmermann, Michael T , Kumar, Rajiv , Ferrer, Alejandro , Singh, Ravinder , Savill, Kristin M. Zimmerman

Mayo Clinic

Journal of Bone and Mineral Research | December 11, 2019 | Volume: 35 | Issue: 4 | Pages: 662-670

10.1002/jbmr.3938 | PMID 31826312 Get It

ABSTRACT Inactivating mutations of the ENPP1 gene are associated with generalized arterial calcification of infancy (GACI) and less often autosomal-recessive hypophosphatemic rickets type 2 (ARHR2). We aimed to investigate the spectrum of phenotypes in a family with monoallelic and biallelic mutations of ENPP1 after identification through whole exome sequencing of a 54-year-old female with biallelic mutation of ENPP1, c.323G > T; p.Cys108Phe and c.1441C > T; p.Arg481Trp. Including the proband, 2 subjects had biallelic mutations, 5 had monoallelic mutations, and 2 had no mutation of ENPP1. The maternal mutation, a known pathogenic variant associated with GACI, was found in 3 subjects with monoallelic mutations, while the paternal mutation, which was not previously reported, was present in 2 subjects with monoallelic mutations. Both subjects with biallelic mutations had bowing of bilateral femurs, periarticular mineral deposition, normocalcemic primary hyperparathyroidism with multigland parathyroidectomy, increased carotid intima-media thickness, and enthesopathy was also noted in one subject. Intact FGF23 was elevated in both subjects with biallelic mutations, while C-terminal FGF23 was only elevated in one and PPi was reduced in one. Subjects with monoallelic mutations did not have periarticular calcifications or bone deformities. To conclude, patients with biallelic GACI causing mutations can survive well into adulthood, and despite the same biallelic ENPP1 pathogenic variants, clinical and biochemical manifestations can significantly differ, and include enthesopathy and primary hyperparathyroidism, which have not been previously described. Although carriers of monoallelic ENPP1 variants appear unaffected by classic disease manifestations, there may be subtle biochemical and clinical findings that warrant further investigation. © 2019 American Society for Bone and Mineral Research.
Fragility Index in Cardiovascular Randomized Controlled Trials
Khan, Muhammad Shahzeb , Ochani, Rohan Kumar , Usman, Muhammad , Yamani, Naser, Murad, M. Hassan , Murad, M Hassan , Usman, Muhammad Shariq , Shaikh, Asim , Khan, Safi U. , Mandrola, John M , Doukky, Rami , Krasuski, Richard A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | December 11, 2019 | Volume: 12 | Issue: 12 | Pages: No page available

10.1161/circoutcomes.119.005755 | PMID 31822121 Get It

Background: Efficacy of an intervention is commonly evaluated using P values, in addition to effect size measures such as absolute risk reduction, relative risk reduction, and numbers needed to treat. However, these measures are not always intuitive to clinicians. The fragility index (FI) is a more intuitive number that can facilitate interpretation but can only be used with binary outcomes. FI is the minimum number of patients who must be moved from the nonevent group to the event group to turn a significant result nonsignificant. In this retrospective analysis, we assessed the robustness of cardiovascular randomized controlled trials (RCTs), which report a positive (statistically significant) primary outcome by using the FI. Methods and Results: We searched Medline from 2007 to 2017 to identify cardiovascular RCTs published in 6 high impact journals ( The Lancet , New England Journal of Medicine , Journal of the American Medical Association , Circulation , Journal of the American College of Cardiology and European Heart Journal ). Only RCTs with sample sizes >500 and a 2-by-2 factorial design or dichotomous primary outcomes were selected. FI was calculated using a defined approach. Among the cohort of 123 RCTs that met inclusion criteria, median FI was 13 (interquartile range, 5–26). In 28 trials (22.8%), FI ranged between 1 and 4. In 37 trials (30.1%), number of patients lost to follow-up was higher than the FI. Pharmaceutical interventions had higher FI compared with other interventions, FI=19 (7–52; P =0.002). Median FI varied according to subspecialty (electrophysiology=2; heart failure=11; interventional cardiology=8; P =0.020) and multiregional RCTs had higher FI=22 (12–53.25; P =0.023). FI did not differ based on risk of bias indicators, funding, or publication year. Conclusions: Considerable variations in FI were observed among cardiovascular trials, suggesting the need for careful interpretation of results, particularly when number of patients lost to follow-up exceeds FI.
Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia
Zanwar, Saurabh , Abeykoon, Jithma P. , Durot, Éric , King, Rebecca L. , Burbano, Gabriela E. Perez, Kumar, Shaji , Gertz, Morie A. , Quinquenel, Anne , Gonsalves, Wilson I. , Cornillet‐Lefèbvre, Pascale , He, Rong , Warsame, Rahma , Novak, Anne J. , Greipp, Patricia T. , Inwards, David J. , Micallef, Ivana N. , Muchtar, Eli , Kourelis, Taxiarchis , Lacy, Martha Q. , Dingli, David , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Johnston, Patrick B. , Thanarajasingam, Gita , Lin, Yi , Kyle, Robert A. , Ansell, Stephen M. , Kapoor, Prashant , Perez Burbano, Gabriela E, Gonsalves, Wilson , Warsame, Rahma , Inwards, David, Micallef, Ivana, Kourelis, Taxiarchis , Dispenzieri, Angela , Witzig, T.E. , Villasboas, Jose, Leung, Nelson , Rajkumar, S Vincent , Ansell, Stephen M , Kapoor, Prashant , Gertz, Morie A , Muchtar, E , Dingli, David , Greipp, Patricia T , Lin, Yi , Quinquenel, Anne , Burbano, Gabriela Perez , Delmer, Alain , Buadi, Francis K. , Habermann, Thomas M. , Go, Ronald S. , Dispenzieri, Angela , Bennani, N. Nora , Witzig, Thomas E. , Villasboas, José C. , Leung, Nelson , Rajkumar, S. Vincent , Le‐Rademacher, Jennifer

Mayo Clinic

American Journal of Hematology | December 9, 2019 | Volume: 95 | Issue: 3 | Pages: 274-281

10.1002/ajh.25697 | PMID 31814157 Get It

AbstractHistological transformation in Waldenström macroglobulinemia (WM) is an uncommon complication, with limited data, particularly regarding the impact of MYD88 L265P mutation on transformation. We examined risk factors and outcomes associated with transformation in WM, highlighting the role of MYD88 L265P mutation. Patients with WM seen at Mayo Clinic, Rochester, USA and University Hospital of Reims, France, between 01/01/1996 and December 31, 2017 were included; 50 (4.3%) of 1147 patients transformed to a high‐grade lymphoma, with median time‐to‐transformation of 4.5 (range 0‐21) years in the transformed cohort. The MYD88 L265P mutation status was known in 435/1147 (38%) patients (406 with non‐transformed WM and 29 patients in transformed cohort). On multivariate analysis, MYD88 WT status alone was an independent predictor of transformation (odds ratio, 7[95%CI: 2.1‐23]; P = .003). Additionally, the MYD88 WT status was independently associated with shorter time‐to‐transformation (HR 7.9 [95%CI: 2.3‐27; P = .001]), with a 5‐year transformation rate of 16% for MYD88 WT vs 2.8% with MYD88 L265P mutated patients. Patients with transformation demonstrated a significant increase in risk of death compared to patients who did not transform (HR 5.075; 95%CI: 3.8‐6.8; P < .001). In conclusion, the MYD88 WT status is an independent predictor of transformation and associated with a shorter time‐to‐transformation. Additionally, transformation conferred an inferior overall survival in patients with WM.
Pleural effusion: An extremely uncommon complication of correctly placed umbilical venous catheter
Sankararaman, Senthilkumar , Kurepa, Dalibor , Kakkilaya, Venkatakrishna , Patra, Kajal Kumar , Gates, Thomas, Patra, K.

Mayo Clinic

Journal of Neonatal-Perinatal Medicine | December 3, 2019 | Volume: 5 | Issue: 3 | Pages: 269-273

10.3233/npm-2012-60112 Get It

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response
Lacy, Martha Q. , Kapoor, Prashant , Hayman, Suzanne R. , Kyle, Robert A. , Kumar, Shaji , Moustafa, Muhamad Alhaj , Rajkumar, S. Vincent , Dispenzieri, Angela , Buadi, Francis K. , Gertz, Morie A. , Dingli, David

Mayo Clinic

Blood | November 17, 2019 | Volume: 124 | Issue: 21 | Pages: 3427-3427

10.1182/blood.v124.21.3427.3427 Get It

Abstract Background: Normalization of serum free light chain ratio (FLCr) following achievement of a complete response (CR) to therapy denotes a stringent CR in multiple myeloma, and is associated with improved overall survival (OS). However, its value in patients achieving less than a CR is not clear. We hypothesized that patients in whom FLCr normalizes with the initial anti-myeloma therapy will have an improved outcome, even in the absence of a CR. Methods: We analyzed the medical records of patients with MM who were evaluated at Mayo Clinic, Rochester, MN between January 2004 and December 2011, seen within 90 days of diagnosis. We selected patients with measurable disease on serum protein electrophoresis, defined as a serum M-spike ≥1 g/dl at the time of diagnosis. Then, we excluded all patients with negative immunofixation for monoclonal M-protein in serum and urine at their first response as well as those who did not have serum FLC results available from the time of their first best response. M protein measurements were collected serially from the time of diagnosis until the time of the first relapse or last follow up date if no relapse was recorded. Progression-free survival (PFS) and OS were analyzed using the Kaplan-Meier method. Results: Out of the 1354 MM patients seen at our institution during this period, a total of 453 patients were included in our study. The median age of the cohort at the time of diagnosis was 65 (range, 29-91); 49% were older than 65 years and 284 (63%) were male. The estimated median follow up for the whole cohort was 66 months (95% CI; 61, 71); 241 patients were alive with a median follow up of 4.7 years (range, 0.4 to 10). Three hundred and seventy three (82%) patients had relapsed following the initial therapy with a median time to progression (TTP) of 19.5 months (95% CI; 18, 22) and PFS of 19 months (95% CI; 17, 20). The median OS for the entire cohort is 67 months (95% CI; 59, 73). The median time to the best first response was 6.9 months (range: 0.3-83 months). At the time of the best first response 154 patients (34%) had normal FLCr. Patients with normal FLCr had a longer PFS (29 vs. 16 months, P< .0001) and OS (91 vs. 58 months, P= .0002). We then examined the impact of FLCr normalization on survival outcomes according to their IMWG response categories. We found that FLCr normalization had a favorable impact on PFS in each of the three groups [very good partial response (VGPR), Partial response (PR), and Stable disease (SD)], However, when looking at the OS, only patients with PR had a better OS associated with a normal sFLC κ/λ ratio (Table 1). Conclusions: Obtaining a normal sFLC ratio appears to confer a more favorable prognosis irrespective of the depth of the response, suggesting an important role for serial-sFLC measurements in disease monitoring even in patients who achieve only a PR to therapy as their best response. This supports the inclusion of sFLC at all levels of response included in the current International Myeloma Working Group (IMWG) criteria. Abstract 3427. Table 1 Effect of FLCr normalization according to IMWG response categories SD PR VGPR Normal FLCr Abnormal FLCr p-value Normal FLCr Abnormal FLCr p-value Normal FLCr Abnormal FLCr p-value Number of patients 7 70 62 157 85 60 PFS, month, median (95% CI) 27 (14, 36) 7 (5, 12) < .02 26 (20, 36) 17 (13, 20) .0005 29 (23, 32) 21 (18, 26) .03 OS, months, median (95% CI) 68 (49, 68) 41 (31, 61) > .1 NR (65, NR) 61 (50, NR) .004 74 (67, 107) 73 (59, NR) > .9 • Abbreviations: NR; statistically not reached •• Progressive disease (PD) was not included because none of the 12 patients achieved a normal FLCr. Disclosures No relevant conflicts of interest to declare.
Quality of Life and Outcomes in Multiple Myeloma Patients
Kochuparambil, Samith T. , Thompson, Carrie A. , Lacy, Martha Q. , Kapoor, Prashant , Hayman, Suzanne R. , Hwa, Yi L. , Case, Jane K., Kumar, Shaji , Paul, Shilpa , Shanafelt, Tait D. , Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Dingli, David , Rajkumar, S. Vincent

Mayo Clinic

Blood | November 17, 2019 | Volume: 124 | Issue: 21 | Pages: 2605-2605

10.1182/blood.v124.21.2605.2605 Get It

Abstract Background: Multiple Myeloma (MM) patients have a substantially reduced Health related Quality of Life (HQOL) at diagnosis (dx) due to disease related symptoms like bone pain (58%) and fatigue (32%). HQOL monitoring is becoming increasingly important, owing to improved survival and the impact of treatment-related toxicity. As a result HQOL assessments are increasingly being used in clinical trials, but the literature regarding the relationship between HQOL and outcomes in MM is sparse. We used the Mayo Clinic “Hematology Patient Reported Symptom Screen” (HPRSS) to assess the impact of HQOL on outcomes in newly dx patients with MM. Methods:We retrospectively reviewed charts of 453 patients with newly dx MM seen at Mayo Clinic, Rochester from 2009 to 2014. All patients who visit Mayo clinic hematology clinic complete a 3-point questionnaire (HPRSS) on pain, fatigue and quality of life (QOL) (scored on a scale of 0-10; with 0 being the least fatigue or pain and 10 being the best QOL). Pain, fatigue and QOL scores documented at the time of dx and at 6 months were collected. JMP version 10 was used for the data analysis. Results: The median age at diagnosis was 67 years (range, 33-95); 60% were male. The estimated median OS for the cohort was 21 m (95% CI19, 23); 387 (85%) of the patients were alive at last follow up and the median OS for the population was not reached. The median (IQR) scores for pain, fatigue and QOL were 4 (2, 6), 3 (1, 5), and 7 (5, 9), respectively. First, we examined the relationship between each of the scores (dichotomized at the median) and the baseline characteristics. Higher fatigue scores were associated with lower Hb and serum albumin and higher beta 2 microglobulin, LDH and marrow plasmacytosis. Higher pain scores were seen in female patients, and associated with higher B2M, serum calcium and lytic bone lesions. Lower QOL scores were associated with lower absolute lymphocyte count and serum albumin levels. Next, we examined the relationship between the scores and the OS from diagnosis. The overall survival was inferior for patients with higher pain scores, fatigue scores and lower QOL scores (Figure). In a multivariable analysis, fatigue scores were most strongly associated with survival outcome. Patients with adverse scores in two or more of pain, fatigue and QOL had significantly inferior outcomes (Figure). In univariate analysis, age, B2M, LDH, FISH high risk and the presence of two or more adverse scores were all significantly associated with poorer OS. In a multivariable analysis, age, LDH and the presence >=2 adverse scores were all associated with shorter OS. Of the 453 patients included in the study, 222 patients had pain, fatigue and QOL scores at 6 month from diagnosis. At 6 months, the median (IQR) scores for pain, fatigue and QOL were 2 (1, 5), 4 (2, 5), and 7 (5, 9), respectively; suggesting improved pain, worsened fatigue and static QOL scores. Improvement in the scores by at least one point was seen in 50%, 49% and 38% for the fatigue, pain and QOL scores. While the pain and fatigue scores at 6 months correlated inversely with OS, improvements in the scores in any of the three were not associated with any improved outcomes. Conclusion: A simple, patient reported scoring system for pain, fatigue, and overall perceived QOL at the time of diagnosis is a powerful predictor of survival outcomes in patients with newly diagnosed MM and should be considered routinely in clinical practice. The results of these patient reported measures can be utilized to develop risk-adapted trials in patients with MM. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.